Lumbrokinase.

EPA shifts eicosanoid production toward the less aggregatory thromboxane A3 and lowers normal platelet aggregation, while lumbrokinase acts on fibrin. The two effects add up on the same physiology and the combination warrants medical supervision.

Ginkgolide B antagonises platelet activating factor, which lowers normal platelet aggregation from a different angle than a fibrinolytic enzyme. Combined use adds two independent pushes in the same direction.

Garlic organosulfur compounds reduce normal platelet aggregation and adhesion. Stacking that with a fibrinolytic enzyme compounds an effect on ordinary clot formation.

Curcumin dampens thromboxane production and platelet activation at higher intakes. Taken with a fibrinolytic enzyme the two effects on normal clotting add together.

Bromelain has its own fibrin-degrading and platelet-modifying activity, so it overlaps directly with what lumbrokinase does. Formulators who combine them should account for the additive load rather than assuming independence.

Gingerols inhibit thromboxane synthase and lower normal platelet aggregation at higher intakes. That runs in the same direction as a fibrinolytic enzyme.

Salicin is converted to salicylate, which dampens platelet cyclooxygenase activity without the irreversible acetylation aspirin causes. Combined with a fibrinolytic enzyme the effect on normal clotting stacks.

High-dose alpha-tocopherol interferes with protein kinase C signalling in platelets and with vitamin K-dependent carboxylation. Both effects run alongside a fibrinolytic enzyme rather than against it.

Vitamin K2 is the cofactor for gamma-carboxylation of clotting factors II, VII, IX and X, so it supports the normal clotting arm that a fibrinolytic enzyme pushes the other way. The two are not contradictory in a formula but their directions must be understood.

Both are enteric-coated proteases marketed for fibrin turnover, and both are protein enzymes that survive the stomach only when the coating holds. Combining them raises total protease load without any trial that measured the pair. Regard the pairing as additive on the same axis, not complementary.

Gamma-glutamyl carboxylase requires reduced vitamin K to activate several coagulation factors; this is settled biochemistry and needs no trial. A fibrinolytic enzyme acts downstream on formed fibrin. The two therefore work in opposite directions on normal clot formation and breakdown, which is worth flagging in a formula that carries both.

EPA competes with arachidonic acid as a substrate for cyclooxygenase, producing thromboxane A3 in place of the more aggregatory thromboxane A2. That is established lipid biochemistry. Paired with a fibrinolytic enzyme the two act at different steps of the same process, platelet activation and fibrin breakdown, so effects on normal clotting can add.

The platelet signal for quercetin comes from cell and ex vivo assays, so it is a marker and not a measured clinical result. Stacked with a fibrinolytic protease the direction of effect on normal clotting is the same. Worth naming in a formula rather than assuming the two are unrelated.

Grape seed proanthocyanidins are reported to blunt platelet activation markers and support endothelial nitric oxide signalling. Those are markers, not outcomes. The overlap with a fibrinolytic enzyme is on the same axis of normal clot formation and breakdown.

Reported effects are on platelet reactivity markers in small groups, which is early-grade evidence. The pairing with a fibrinolytic protease is additive in direction. Flag it rather than present it as a designed combination.

Nitrate reduction by oral bacteria and subsequent conversion to nitric oxide is a well described pathway with consistent effects on blood pressure markers. Nitric oxide also dampens platelet activation. Alongside an enzyme acting on fibrin, the combined direction on vascular tone and clot handling is the same.

Nitric oxide synthase converts L-arginine to nitric oxide and citrulline, textbook enzymology. Nitric oxide relaxes vascular smooth muscle and inhibits platelet adhesion. That places arginine on the same side of vascular tone and clot handling as a fibrinolytic enzyme, without any combination trial having measured the pair.

Serine proteases are acid labile and are denatured in a strongly acidic stomach, which is why oral preparations use enteric coating. Adding a hydrochloride acidifier in the same dose window increases the acid load the coating must withstand. Separating the two in time is the practical consequence.

Pepsin cleaves peptide bonds preferentially at aromatic residues and is active at low pH. An unprotected enzyme preparation is a substrate for it. Co-dosing a pepsin product with a proteolytic enzyme intended to act beyond the stomach works against the second one.

Pancreatin and plant protease blends carry trypsin, chymotrypsin, papain or bromelain activity that does not distinguish a supplemental enzyme from dietary protein. Dosing them together in one capsule window puts one product's active in the other's substrate pool. Formulators usually separate them for that reason.

CoQ10 acts as an electron carrier in the mitochondrial respiratory chain and as a lipid-phase antioxidant, while lumbrokinase acts extracellularly on fibrin. There is no shared pathway and no combination trial. The pairing is a formulation choice, not a demonstrated interaction.